Intervention Protocol

Omega-3 polyunsaturated fatty acids for non-alcoholic fatty liver disease

  1. Siheng Lin1,2,
  2. Kun Xiao3,
  3. Yangyang Liu4,
  4. Peizhu Su5,
  5. Pingyan Chen6,
  6. Yali Zhang2,
  7. Yang Bai2,*

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 20 NOV 2013

DOI: 10.1002/14651858.CD010838

How to Cite

Lin S, Xiao K, Liu Y, Su P, Chen P, Zhang Y, Bai Y. Omega-3 polyunsaturated fatty acids for non-alcoholic fatty liver disease (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.: CD010838. DOI: 10.1002/14651858.CD010838.

Author Information

  1. 1

    Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Department of Gastroenterology, Hangzhou, Zhejiang, China

  2. 2

    Nanfang Hospital, Southern Medical University, Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Guangzhou, Guangdong, China

  3. 3

    Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangdong Provincial Key Laboratory of Gastroenterology, Guangzhou, Guangdong, China

  4. 4

    Zhiguang Biotechnology Limited Company, Department of Pharmaceutical Research and Development, Guangzhou, 510663, China

  5. 5

    Zhuangjiang Hospital, Southern Medical University, Department of Gastroenterology and Hepatology, Guangzhou, Guangdong, China

  6. 6

    Southern Medical University, Department of Biostatistics, Guangzhou, Guangdong, China

*Yang Bai, Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, No.1838, Guangzhou North Avenue, Guangzhou, Guangdong, 510515, China. baiyangsmu@gmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 20 NOV 2013

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To evaluate the beneficial and harmful effects of omega-3 polyunsaturated fatty acids supplementation in people with non-alcoholic fatty liver disease.